Eli Lilly Is Buying 5-MeO-DMT. I Don't Think That's Good News.
On July 16, 2026, Eli Lilly announced it had agreed to acquire AtaiBeckley for $6.75 per share in cash — roughly $2.8 billion — plus contingent payments of up to $2.50 per share tied to development and regulatory milestones over the seven years following the close. All in, about $3.8 billion. AtaiBeckley shareholders vote on September 8. It is the largest psychedelic deal in history, and the buyer is the most valuable pharmaceutical company in the world.
What Lilly is buying is a molecule called BPL-003: an intranasal, synthetic formulation of 5-MeO-DMT, headed into Phase 3 trials for treatment-resistant depression, carrying FDA Breakthrough Therapy Designation. Also in the package is VLS-01, a buccal film of DMT, currently in Phase 2b.
Half the field read that news as vindication. The molecules are finally being taken seriously. Real capital, real trials, real regulatory pathways, real access for people who are suffering and have run out of options.
I read it differently. I've spent years doing preparation and integration work with people who work with these medicines (in private practice, in clinical trials and in the retreat space in costa rica) and what I saw in that press release was a business model I've already watched play out once. It was called ketamine. And in the version most patients actually receive (intranasal spray), it doesn't work very well — not because the molecule is weak, but because nobody is doing the work. Psychiatrists aren’t trained in working with psychedelics, they are trained in prescribing medication. And therefore they aren’t guiding individuals through true transformative work that these medicines have the potential for.
Let me be specific about why.
What Lilly is actually buying
The Phase 2b data is genuinely impressive on paper. 193 patients, a single intranasal dose. At day 29, the 8 mg group showed a 12.1-point mean reduction on the MADRS depression scale; the 12 mg group, 11.1 points; the 0.3 mg low-dose comparator, 5.8 points. Effects were largely sustained through day 57. A single dose.
But read one more line from that trial, because it's the line that tells you what this drug is being built to be: the majority of patients were deemed ready for discharge at the 90-minute post-dose assessment. Average time to discharge readiness came in around two hours. Lilly's own release describes "an in-clinic visit lasting approximately two hours on average."
Two hours. In and out.
That is not an incidental detail. That is the entire commercial thesis. A psilocybin dosing day in the major trial protocols runs six to ten hours with two trained facilitators in the room — a staffing model that is expensive, slow, and hard to scale across a health system. A two-hour in-clinic visit fits into a psychiatric practice's existing schedule. It bills like a procedure. You can run four of them in a morning.
One more detail worth noticing: Lilly's press release never uses the word "psychedelic." The pipeline is described as "rapid-acting neuroplastogens" that restore "synaptic plasticity." That's not an accident of style. That's positioning. The mystical experience is a side effect to be managed, and the neurobiology is the product.
We already ran this experiment. It was called ketamine.
In 2019 the FDA approved Spravato — esketamine nasal spray — for treatment-resistant depression, with a REMS safety program attached. Here's what that REMS program requires: administration at a certified site, with a prescriber present, and monitoring for at least two hours and until sedation, dissociation and respiratory depression have resolved. Vital signs before dosing, blood pressure monitoring during, an assessment before discharge.
Here's what it does not require: Psychotherapy. Preparation. Integration. Any psychological support of any kind. Not one minute of it. The federal framework governing the rollout of a dissociative psychedelic (and technically it’s a psycholytic) into American psychiatry has exactly zero requirement that anyone help the patient make meaning of what they experienced; which I would argue is the most important element of working with these medicines. Otherwise we are treating all of it like we do all psych medications.
And in January 2025 the FDA approved Spravato as a standalone monotherapy — patients no longer need to be on an oral antidepressant alongside it. Note the direction of travel. Every regulatory revision has moved away from the drug being embedded in anything. Fewer wrappers, not more.
It worked, commercially. Spravato brought in $1.7 billion in 2025, with fourth-quarter sales of $503 million — up 69% year over year, a $2 billion annual run rate. List price runs $590 to $885 per dose for the drug alone, before the clinic's observation fee. An uninsured year of treatment can run $24,000 to $50,000 and up.
So here is what I actually see in practice. A patient goes to a ketamine or Spravato clinic. They're put in a room — sometimes a nice room, sometimes a recliner behind a curtain. Nobody has prepared them. Nobody has asked what they're bringing, what they're afraid of, what happened to them at eleven years old. They're handed a device, or they've brought their own, and they spend the session on their phone (true story). No eye mask. No music chosen with any intention. No one sitting with them. Nobody has told them that the whole point is to go inward.
Vitals are taken. Two hours pass. They're discharged into a parking lot, alone, still soft and open and porous, and told to come back Thursday.
The psychiatrist bills. The pharmaceutical company books revenue. The patient goes home with a strange afternoon they don't have language for, and three weeks later reports that it "didn't really do anything."
Of course it didn't. Nobody did the work.
The part nobody wants to say out loud: this is politics
You cannot understand why this deal happened in July 2026 without understanding what happened in April 2026, and what happened before that in 2024.
The FDA spent years positioning itself to lead on psychedelics, and then the flagship program fell apart. On June 4, 2024, an FDA advisory committee voted 9–2 that Lykos Therapeutics' MDMA-assisted therapy was not effective for PTSD, and 10–1 that its benefits did not outweigh its risks. The agency issued a Complete Response Letter that August — later made public — citing functional unblinding across both Phase 3 trials, selection bias, thin durability data, and a pattern of systematically not recording "positive" or "favorable" effects as adverse events.
Sit with what actually sank that application. A significant part of the problem was that the therapy and the drug were inseparable, and the FDA does not know how to evaluate therapy. It regulates molecules. It has no mechanism for assessing whether the person in the room knew what they were doing.
There were two possible responses to that. One: build the regulatory capacity to evaluate the therapeutic container — training standards, credentialing, protocol fidelity. Two: stop approving drugs that need a container.
We went with option two.
On April 18, 2026, President Trump signed Executive Order 14401, "Accelerating Medical Treatments for Serious Mental Illness." It directs the FDA to issue Commissioner's National Priority Vouchers to psychedelic drugs meeting Breakthrough Therapy criteria — compressing review timelines from ten to twelve months down to one or two — and directs HHS to spend at least $50 million through ARPA-H partnering with states on psychedelic programs. Six days later, the FDA issued three national priority vouchers (psilocybin for treatment-resistant depression, psilocybin for major depressive disorder, methylone for PTSD) and cleared the first U.S. IND for an ibogaine derivative.
Read that order looking for the words that matter to a clinician. Who administers these treatments. What training they need. What preparation and integration are required. What the psychological support standard is. None of it is in there. Not a line. The order accelerates approval. It is silent on the standard of care.
The market understood it perfectly. Compass Pathways jumped 42% in a single session. AtaiBeckley rose 22%. GH Research rose 17%. Some smaller names ran up as much as 187%. Three months later, Lilly agreed to pay a roughly 40% premium over AtaiBeckley's one-month average price.
Now here's my read, and I want to be clear that it is a read — an inference from timing and incentives, not something anyone has confessed to. I don't believe this administration underwent a moral awakening about consciousness, trauma, and the treatment of veterans. I think somebody looked at a sector where a stroke of a pen could re-rate an entire asset class overnight, and signed. The order did exactly what an order designed to move stock prices would do, and nothing that an order designed to protect patients would do. Judge it by what it contains.
I'll steelman the other side, because it deserves it. There are people inside this push — including veterans and their advocates — who believe in it sincerely, and PTSD in that population is a genuine emergency that has outlasted every conventional treatment we've thrown at it. Sincerity and self-dealing are not mutually exclusive, and both can be operating here. But sincerity doesn't change what the document says. And what it says is: go faster.
So when colleagues tell me this is a monumental shift in how our government thinks about consciousness and healing, I don't see it. I see a deregulatory action with a very short distance between the signature and the share price, and a compound — BPL-003, two hours, no therapy required — that is shaped exactly like the thing this new pathway was built to approve.
The colonization question — and the version of it that's actually true
There's a version of this critique circulating that goes: big pharma is stealing a sacred indigenous toad medicine that native peoples spent millennia learning to respect.
I want to make this argument, but I want to make the one that survives contact with the record — because the true version is more damning, not less.
5-MeO-DMT does have a genuine indigenous lineage. It occurs as a major constituent in the resin of Virola theiodora and related trees, prepared as snuffs by peoples of the Amazon and Orinoco basins. It sits alongside the broader tryptamine snuff traditions built on Anadenanthera peregrina — yopo, or cohoba — whose archaeological trail runs back more than four thousand years across what is now Argentina, Chile, Peru, Colombia and the Caribbean, and which was first described in writing by Europeans in 1496. Those are real traditions, with real ceremonial architecture, real preparation, real specialists, real containment built over millennia.
The toad is a different story. Researchers writing in the journal Psychedelics have called the popular narrative around Incilius alvarius an instance of "fabricated ancestrality." The compound was first synthesized in 1936. It was identified in the toad's secretion in 1965. Its popularization as a smoked medicine traces to 1984 and an underground pamphlet by Ken Nelson, writing as "Albert Most." The Comcáac (Seri) — the people most often invoked as the ancestral keepers of toad medicine — were, by the documented account, introduced to the practice around 2011, through a foundation working to address methamphetamine use among their youth. Permits for "authentic" ceremonies were later sold for $500 each. Toad secretion has reached $50,000 per kilogram on international markets. And the toad itself is now under real ecological pressure from harvesting.
So the honest telling is this: an ancestral frame was manufactured to give a market cultural legitimacy, and indigenous people were positioned as the credentialing authority for a practice that had been sold to them.
That doesn't weaken the objection to Lilly. It sharpens it. Extraction already happened once — the retreat economy took the molecule, wrapped it in a borrowed lineage, and monetized it. Now the pharmaceutical industry takes the same molecule, strips the borrowed lineage off entirely, replaces it with a REMS program, and monetizes it again.
Both moves do the same thing: they take the substance and discard the container. Lineage traditions — the real ones, the Virola and yopo traditions, the ayahuasca traditions, peyote in the Native American Church, iboga among the Bwiti — spent generations building the container. Who may sit. Who may serve. What is done before, and what is done after. What the community owes the person who journeys. What the person owes the community.
The molecule was never the medicine. The container was the medicine. Everyone who commercializes this keeps making the same error, in both directions.
And the practical consequence for indigenous communities is not abstract. When a compound becomes an FDA-approved, DEA-rescheduled pharmaceutical product with patent protection, the traditional practice it was extracted from doesn't get legitimized — it gets outcompeted, and often criminalized by contrast. There is a legal version now, and it belongs to Lilly. Everything else is the unregulated fringe.
Psychiatrists are prescribers. That is not an insult — it's a job description.
I want to say this plainly, because the field keeps being polite about it and patients keep paying the cost.
The overwhelming majority of psychiatrists administering these medicines are not psychedelic-informed clinicians. They are not trained in preparation. They are not trained in the somatic and relational skill of sitting with someone in a non-ordinary state. They are not trained in integration — the actual clinical labor of taking what surfaced and metabolizing it into changed behavior, changed relationships, a changed nervous system. Even though it's there if they chose to.
They are trained to prescribe, to monitor, and to manage adverse events. That is a real and necessary skill set. It is not this one.
The gap between those two things is where patients fall. Because these medicines don't heal anyone. They open something. What comes through that opening — the memory, the grief, the part of you that has been carrying something since childhood, the encounter that dissolves your sense of self entirely — that material has to be worked. Held, tracked, titrated, returned to over weeks. Otherwise it's just a strong experience that fades, and the person concludes they're one of the ones it doesn't work on.
And 5-MeO-DMT is not a gentle candidate for this model. It is arguably the most ontologically destabilizing compound we know of. It can take a person's sense of self apart completely in under a minute. People come back from it having had an experience they cannot fit into the story they've been living in. That is precisely the material that requires a trained container, not a blood pressure cuff and a discharge form.
Two hours to readiness for discharge is a measure of hemodynamic stability. It is not a measure of psychological readiness for anything.
The case for the other side — because it's not nothing
I don't want to pretend this is easy. The people arguing for broad access are not fools, and some of them are my colleagues.
Treatment-resistant depression is lethal. There are people who have failed six medications and two rounds of TMS, who don't have access to a $12,000 retreat in Mexico or a therapist with $40,000 of psychedelic training, and who will not survive another decade of this. Underground access is unregulated, uninsured, and rife with practitioner abuse — the ceremonial world has its own significant harm record, and "trained facilitator" is not a protected term. Insurance coverage only follows FDA approval. Manufacturing standards and dose verification only follow pharmaceutical production. If your standard is harm reduction at population scale, an approved, standardized, monitored 5-MeO-DMT product is a serious argument.
I take that seriously. What I don't accept is the claim that we have to choose between access and adequacy — that the only way to reach many people is to reach them badly. That's not a scientific finding. That's a staffing cost.
What the inner work actually looks like
Here's the alternative, and it isn't exotic.
Preparation is real clinical work: several sessions establishing what the person is bringing, mapping their trauma history, identifying the protective parts that will fight the medicine, building nervous system capacity, setting intention, and establishing informed consent that includes the possibility of terror.
The session itself has a container. Eye mask on. Music chosen deliberately. Phone off and out of the room. A trained sitter or guide present the entire time — not a monitor charting vitals, a clinician who knows how to stay regulated while someone else's system comes apart, who knows when to speak and, far more often, when not to. The instruction is simple and total: go inward. Trust what comes. Don't manage it. Above all else, surrender.
And then integration, which is where the actual change lives: weeks of work translating a non-ordinary experience into ordinary life. What did that part of you need? What are you going to do differently on Monday? For clinicians trained in IFS, EMDR, and somatic approaches, this is familiar territory — non-ordinary states surface exactly the material we're already trained to work with. That's the point. Psychedelic-assisted therapy is therapy. The medicine accelerates access. The clinician does the work.
That is a different intervention from a nasal spray and a two-hour discharge. Comparing their outcomes and concluding anything about the molecule is a category error.
Where this leaves us
I don't think Lilly is going to slow down, and I'm not asking for the compound to stay illegal. I'm saying that approval is not the finish line, and that the standard of care is being written right now — in trial protocols, REMS documents, and executive orders — by people whose incentives point toward the cheapest possible version.
If you're a clinician: get trained. Actually trained. (Reach out. I can point you in the right direction) The prescribers are going to need us, and if we aren't ready, the two-hour model becomes the standard by default.
If you're someone considering this work: ask who is going to be in the room with you, what training they have, what happens before, and what happens after. If the answer is "we'll check your blood pressure and you can head out around 4," that is not psychedelic-assisted therapy. That's a prescription and your results will be no different than what you’ve already tried via psych meds.
The molecule was never the medicine.
